Solaris Endovascular, Inc.

About

Solaris Endovascular is a growth-stage medical device company developing next-generation drug-eluting covered stents designed to extend dialysis access life and improve vascular outcomes. The company currently generates $5M in OUS sales with its base product, Solaris SX, approved in 45 countries including MDR CE Mark. Its next generation product, Solaris DE, combines the Solaris SX mechanical scaffold, electrospun PTFE barrier, with a biodegradable sirolimus-eluting polymer to address both restenosis and structural failure in dialysis access circuits. The company’s phase II DEScover clinical study has completed enrollment of 120 subjects with no safety concerns at 30 days, and six-month interim results demonstrated 95% Target Lesion Primary Patency, significantly outperforming historical results for angioplasty and conventional covered stents.